Plain-English translation of NCT07599176 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a gentler form of stem cell transplantation for people with sickle cell disease or beta-thalassemia. The procedure uses (a medication that weakens your immune system), a modest dose of whole-body radiation, and (another immune-calming medication) to prepare your body to accept stem cells from a matched family member donor. The goal is to help these donated cells take root and grow strong enough to replace the faulty cells causing your disease.
Current transplant approaches sometimes result in the donated cells not engrafting well or engraftment being lost over time. Researchers want to find the right balance—strong enough conditioning to help the new cells stick around, but gentle enough to avoid serious side effects—so more patients can benefit from transplant as a cure.
You likely qualify if…
You likely don't qualify if…
You will undergo chemotherapy and radiation to prepare your body for the transplant, then receive stem cells from your matched donor. You will stay in the hospital for several weeks after transplant and be closely monitored for complications. You will have frequent blood tests and clinic visits over the first few months, then ongoing follow-up visits for years to track how well the transplant is working and how you are doing physically and emotionally. The entire study involves regular hospital or clinic visits over several years.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
United States